-
radiopharmaceutical for
unsealed source radiotherapy, Iodine-131
Tositumomab (branded as
Bexxar), for the
treatment of non-Hodgkins lymphoma. It is
classified as a IgG2a...
- by a placebo. Ra-223-chloride is an alpha-emitting bone
targeting agent.
Bexxar, a
radioligand therapy using the
radioisotope I-131+Tositumomab (a murine...
-
cancer Yttrium-90-ibritumomab
tiuxetan (Zevalin) and Iodine-131-tositumomab (
Bexxar)
Refractory lymphoma 131I-MIBG (metaiodobenzylguanidine) Neuroendocrine...
-
Approval Information –
Licensing Action "Why Good
Drugs Sometimes Fail: The
Bexxar Story". 2013-08-26. "EU/3/03/136".
European Medicines Agency. Retrieved...
- 2003, the FDA
approved the tositumomab/iodine (131I)
tositumomab regimen (
Bexxar),
which is a
combination of an iodine-131
labelled and an
unlabelled anti-CD20...
-
nephritis etc.
Tosatoxumab mab
human Staphylococcus aureus Tositumomab Bexxar mouse CD20 Y
follicular lymphoma Tovetumab mab
human PDGFRA cancer Tralokinumab...
- cancer.
Other examples include radio-labelled anti-CD20
antibodies (e.g.
Bexxar) for
treating lymphoma, Radium-223 for
treating bone metastases, Lutetium-177...
-
radioactive molecules known as radioimmunotherapy.
These include Zevalin and
Bexxar.
Rituximab has also been used in
small numbers of
patients in combination...
- are
concerned with
immunological and
oncological targets.
Tositumomab –
Bexxar – 2003 – CD20
Mogamulizumab –
Poteligeo –
August 2018 – CCR4 Moxetumomab...
-
developing ****ays for what was a
commercial product for non-Hodgkins lymphoma,
Bexxar, a
radiolabeled antibody.
Later on, in 2011, he
presented on the characterization...
